Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans.
about
Effect of diet-induced obesity on acute pancreatitis induced by administration of interleukin-12 plus interleukin-18 in mice.Evaluation and integration of 49 genome-wide experiments and the prediction of previously unknown obesity-related genesGenome-wide association study identifies variants at the IL18-BCO2 locus associated with interleukin-18 levels.The role of interleukin-18 in the metabolic syndrome.Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome.Selected dietary flavonoids are associated with markers of inflammation and endothelial dysfunction in U.S. women.Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.Increased expression of IL-18 in the serum and islets of type 1 diabetics.Genetic variation within IL18 is associated with insulin levels, insulin resistance and postprandial measures.Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns.Inflammatory and oxidative stress responses to high-carbohydrate and high-fat meals in healthy humansA Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes MellitusIL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistanceAssociation of adiponectin and metabolic syndrome in women.Association of interleukin-18 gene polymorphism with body mass index in womenInterleukin-18, together with interleukin-12, induces severe acute pancreatitis in obese but not in nonobese leptin-deficient mice.Important genetic checkpoints for insulin resistance in salt-sensitive (S) Dahl rats.Circulating IL-18 and the risk of type 2 diabetes in women.Inflammation during obesity is not all bad: evidence from animal and human studies.Potential role of interleukin-18 in patients with rheumatoid arthritis-associated carotid intima-media thickness but not insulin resistancePotential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease.Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease.Transcriptional and post-translational regulation of adiponectin.Caspases and inflammasomes in metabolic inflammation.Interleukin-18 suppresses adiponectin expression in 3T3-L1 adipocytes via a novel signal transduction pathway involving ERK1/2-dependent NFATc4 phosphorylation.Per os colchicine administration in cholesterol fed rabbits: Triglycerides lowering effects without affecting atherosclerosis progress.Molecular and immunohistochemical effects of metformin in a rat model of type 2 diabetes mellitus.Felodipine downregulates serum interleukin-18 levels in rats with fructose-induced metabolic syndrome.Adult subjects with Prader-Willi syndrome show more low-grade systemic inflammation than matched obese subjects.The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus.Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors, C-reactive protein and adiponectin in morbidly obese patients.Interleukin-18: Biological properties and role in disease pathogenesis.Interleukin-18 and testosterone levels in men with metabolic syndrome.Expression of mRNA and protein of IL-18 and its receptor in human follicular granulosa cells.Interleukin-18 serum level is elevated in type 2 diabetes and latent autoimmune diabetes.Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.Elevation of plasma interleukin-18 concentration is associated with insulin levels in patients with systemic lupus erythematosus.PKC-β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis.Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications.Association of C-Reactive Protein and Other Markers of Inflammation with Risk of Complications in Diabetic Subjects.
P2860
Q33385913-ED035FF2-0FC1-4CFA-A616-FC11BDBB06DCQ33731942-ABA05A14-FC53-4E0D-9C60-B9AA85397E21Q33740363-70BF5F49-4FBD-411B-B4AE-25A07136FCC4Q33804391-70EC3144-EC9E-4BC7-A040-9528247254ECQ34573680-8309FD4D-F3A5-4AC5-8045-9C459B003240Q34675053-FFFAAF3A-077A-4CF0-A2B7-DB3061E1E2CDQ34779049-14F2C275-BC28-4690-8F12-C76606E4ACD0Q35044541-AE50ECA3-4DE3-44EA-AB90-90A28E1B61A5Q35172378-EFD36AC3-D740-424D-B1CC-74F6346A0B9CQ35829203-BFB54B97-F6ED-4D10-A3B0-7137D2BDDFBCQ35838041-376EA4AD-0BBD-450C-B88C-FC968CCCE66EQ35941368-2705C069-A230-4EC2-8221-CFACA4A05ADBQ36005876-C1FDC620-26D7-4809-B5AD-7B5220F1F6B3Q36212090-4844B962-7A58-4F65-8958-78B50A6C1061Q36287002-06C30D30-4132-4393-9374-DEE3871A1129Q36725696-1AC62772-4E89-4DFB-9707-B6099617622AQ36761492-88FF3C09-4CEB-470E-8E02-DCD662548BF7Q37136196-4F8172B5-C495-45DC-B0F0-234D1C3D0AF1Q37174503-56944F40-6C07-4928-8E6C-E98EB3BE95B6Q37296393-3432968E-4051-43E9-A86B-F824ACB3F2FFQ37298658-4D483D7D-BF86-468F-A8CC-12A527E4EEA5Q37420086-7B2A2A73-A44F-4031-9013-FE69E8C046BEQ37650762-1F43AB2A-F8B6-4E9B-A613-8BD27707941EQ38187337-D510D84F-B5C1-43BA-9471-45CFB44981A1Q38295214-ECE6C0A6-B920-4008-B3D4-8269DC3FBA53Q41675413-DC279535-F58B-49C4-A7B0-79EC207383F3Q41820766-20DB5811-D8D7-4184-94F4-391E36E1CE1FQ45918376-E2ED656B-F8E5-48EC-83D7-0FC40CC36336Q46685753-A181E563-DBA4-45EF-A03F-D8903A2607FCQ46878866-A5F83456-E5E4-4D64-9CDA-7F1C1C9C357AQ47280913-8F8AD8F3-750D-43ED-8FF0-6C92F6FD481EQ47285927-9705CAE4-6CCE-4D84-BFC8-75BEE0FD91FBQ47424568-F5B19115-AA9F-4A2D-BAE3-6EED1E1D95C2Q48534581-B1B41776-94AD-41A7-AA78-B3036036B5D6Q50021277-ED766077-DD65-4C12-84B3-7A010FCEF68EQ51391705-69932DD2-89F3-4E16-8131-6565801CC17DQ51498308-54C3DC49-F9D6-433C-B62E-58D9A6EF83C1Q52956251-EF8E0645-4077-4563-9542-A31D663051FDQ54260312-91BC7280-5B0C-4FFB-AF69-5AB3EA53A61CQ55221890-907C0537-6103-4070-B27C-8EA194B127B8
P2860
Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@ast
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@en
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@nl
type
label
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@ast
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@en
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@nl
prefLabel
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@ast
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@en
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@nl
P2093
P1433
P1476
Elevated plasma interleukin-18 ...... betic and non-diabetic humans.
@en
P2093
Annika Berntsen
Lisbeth B Perstrup
Peter Eskildsen
P304
P356
10.1016/J.CLIM.2005.07.008
P577
2005-08-19T00:00:00Z